Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.73 |
| ▸ | MEN1 | O00255 | 7/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | CASP6 | P55212 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | TYMS | P04818 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | S100B | P04271 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162903 | 0.88 | KMT2A (0.57) | KMT2AMEN1KDM4EALDH1A1RXFP1 | |
| SCHEMBL5538804 | 0.87 | KDM4E (0.74) | KMT2AMEN1KDM4EALDH1A1RXFP1 | |
| SCHEMBL14172750 | 0.85 | KMT2A (0.72) | KMT2AMEN1KDM4EALDH1A1RXFP1 | |
| SCHEMBL1518037 | 0.83 | ALDH1A1 (0.68) | KMT2AMEN1KDM4EALDH1A1RXFP1 | |
| SCHEMBL28563147 | 0.83 | NPC1 (0.70) | KMT2AMEN1KDM4EALDH1A1RXFP1 | |
| SCHEMBL5150543 | 0.82 | KMT2A (0.70) | KMT2AMEN1KDM4EALDH1A1RXFP1 | |
| SCHEMBL16602052 | 0.82 | KMT2A (0.70) | KMT2AMEN1KDM4EALDH1A1RXFP1 | |
| SCHEMBL32670799 | 0.81 | POLB (0.59) | KMT2AMEN1KDM4EALDH1A1RXFP1 | |
| SCHEMBL5535536 | 0.81 | KMT2A (0.69) | KMT2AMEN1KDM4EALDH1A1RXFP1 | |
| SCHEMBL1514286 | 0.81 | L3MBTL1 (0.73) | KMT2AMEN1KDM4EALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | claimed |
| WO-2007030939-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | claimed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| WO-2007030939-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | KMT2A 4267/4885MEN1 3865/4885KDM4E 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.